Du Publishes Two Studies That Describe an Improved Approach to Bone Marrow Transplant

Du Publishes Two Studies That Describe an Improved Approach to Bone Marrow Transplant

WVU cancer researcher and Assistant Professor of Pharmaceutical Sciences Wei Du, MD, PhD, teamed up with researchers from Cincinnati Children’s Hospital Medical Center to focus on improving outcomes and reducing side effects of traditional stem cell transplant. Their work was recently published in Leukemia, one of the top journals in hematology.

The studies identify an innovative drug that targets Cdc42, a member of one of the Rho GTPase family, which increases bone marrow accessibility and therefore improves stem cell transplant outcome. This project is an extension of previous research in the field of Rho GTPase family in hematopoiesis and is intended to address the urgent and important need for stem cell transplantation. Dr. Du’s work offers a novel preparative regimen for stem cell transplantation in treating bone marrow failure and other blood diseases. They are currently working on establishing improved methods for blood stem cell harvest and transplantation that could significantly impact future stem cell therapies for patients with leukemia and other blood cancers.

A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells.

Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization

In the News:

Two Studies Describe Improved Approach to Bone Marrow Transplant - Cincinnati Children's Newsroom

  • WVU Public Health research included in Physical Activity Guidelines by the federal government

    WVU Public Health research included in Physical Activity Guidelines by the federal government

    New physical activity guidelines being promoted by the U.S. Department of Health and Human Services references research by two WVU Public Health professors.

    Read More

  • WVU in the news—Richard Goldberg: A transformative leader in cancer research

    W est Virginia University’s Cancer Institute is well-known for its treatment and innovation. Leading the institute is Dr. Richard Goldberg, who has not only established himself as a transformative leader but also a potent researcher and educator. A native of upstate New York, the renowned gastrointestinal cancer expert came to Morgantown about two years ago. Goldberg previously worked at The Ohio State University’s Wexner Medical Center, where he served as the Klotz Family Professor of Cancer Research, the physician‐in‐ chief of the James Cancer Hospital, the associate director of the Ohio State Comprehensive Cancer Center and the acting division director of the Division of Medical Oncology. Before that, he also worked at the University of North Carolina and the Mayo Clinic. Goldberg is one of many world-class physicians recruited by WVU Medicine during the past few years, whose research has resulted in more than 300 peer-reviewed publications, including those in the New England Journal of Medicine, the Journal of the American Medical Association and the Journal of Clinical Oncology

    Read More

  • Bonnie’s Bus receives $25,000 grant to provide patient navigation services

    Bonnie’s Bus receives $25,000 grant to provide patient navigation services

    The WVU Cancer Institute is among six organizations to receive an inaugural Medline Breast Cancer Awareness grant, which is awarded to organizations to further the mission to eradicate breast cancer and provide counseling. The grant drives awareness around prevention and early detection by providing support to organizations that provide direct patient care.

    Read More